Incurred loss on account of Rs 16 crore forex losses in Q2: JR Vyas, Dishman Pharma

JR Vyas, MD, Dishman Pharma in an interview with ET Now talks about the loss that the company incurred in the second quarter.

If you could first talk about why you clocked a loss of Rs 6.3 crores this time?

This is because we had to take forex losses of 16 crores.

Could you give us an indication of the growth that you are currently seeing in CRAMS as well as your molecule business and where do you see the growth till the end of the year?

Standalone EBITDA is higher at 26% but this forex losses of 16 crores has wiped out our profitability for the quarter. This will not happen in the next quarter because we have already taken mark-to-market losses at Rs 60 a dollar.